GBTP Stock Overview
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
Guerbet SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €17.04 |
| 52 Week High | €19.16 |
| 52 Week Low | €15.36 |
| Beta | 0.71 |
| 1 Month Change | 0% |
| 3 Month Change | 1.43% |
| 1 Year Change | 6.37% |
| 3 Year Change | -39.03% |
| 5 Year Change | -71.46% |
| Change since IPO | -38.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| GBTP | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | -1.4% | -1.4% |
| 1Y | 6.4% | -7.8% | -2.4% |
Return vs Industry: GBTP exceeded the UK Medical Equipment industry which returned -7.4% over the past year.
Return vs Market: GBTP exceeded the UK Market which returned -2.4% over the past year.
Price Volatility
| GBTP volatility | |
|---|---|
| GBTP Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: GBTP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine GBTP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1926 | 2,839 | David Hale | www.guerbet.com |
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services.
Guerbet SA Fundamentals Summary
| GBTP fundamental statistics | |
|---|---|
| Market cap | €212.06m |
| Earnings (TTM) | -€42.36m |
| Revenue (TTM) | €775.10m |
0.3x
P/S Ratio-4.7x
P/E RatioIs GBTP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GBTP income statement (TTM) | |
|---|---|
| Revenue | €775.10m |
| Cost of Revenue | €191.23m |
| Gross Profit | €583.87m |
| Other Expenses | €626.23m |
| Earnings | -€42.36m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.36 |
| Gross Margin | 75.33% |
| Net Profit Margin | -5.47% |
| Debt/Equity Ratio | 96.5% |
How did GBTP perform over the long term?
See historical performance and comparison